Browse by author
Lookup NU author(s): Dr Othman AlmusaimiORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA). Peptides present a promising opportunity to address serious infections that may be challenging to manage through other means. Peptides exhibit the capability to leverage various mechanisms, and in some cases, multiple mechanisms are employed for this purpose. Despite the initial approval dating back to 1955, the FDA recently approved an echinocandin peptide just last year. The ongoing approvals underscore the significance of peptides in addressing ongoing medical challenges. Approximately 22 peptide therapeutics with an antibacterial and antifungal spectrum are currently undergoing various phases of clinical trials, showing promising results. In this review, antimicrobial and antifungal peptides are analyzed in terms of their chemical structure, indication, mode of action, and development journey, concluding with their arrival in the pharmaceutical market.
Author(s): Al Musaimi O
Publication type: Article
Publication status: Published
Journal: Antibiotics
Year: 2025
Volume: 14
Issue: 2
Online publication date: 07/02/2025
Acceptance date: 06/02/2025
Date deposited: 24/02/2025
ISSN (electronic): 2079-6382
Publisher: MDPI
URL: https://doi.org/10.3390/antibiotics14020166
DOI: 10.3390/antibiotics14020166
Data Access Statement: Data sharing is not applicable
Altmetrics provided by Altmetric
